{
    "clinical_study": {
        "@rank": "65401", 
        "arm_group": [
            {
                "arm_group_label": "OTX-TPa", 
                "arm_group_type": "Experimental", 
                "description": "OTX-TPa is a hydrogel punctum plug eluting travoprost in sustained release of ~4\u00b5g/day over approximately 2 months.  For study masking purposes, subjects in this arm will also have natural tears drops administered."
            }, 
            {
                "arm_group_label": "OTX-TPb", 
                "arm_group_type": "Experimental", 
                "description": "OTX-TPb is a hydrogel punctum plug eluting travoprost in sustained release of ~3\u00b5g/day over approximately 3 months.  For study masking purposes, subjects in this arm will also have natural tears drops administered."
            }, 
            {
                "arm_group_label": "Timolol", 
                "arm_group_type": "Active Comparator", 
                "description": "Timolol Maleate (0.5%) ophthalmic solution dosed twice daily (BID). For study masking purposes, subjects in this arm will also have a hydrogel punctum plug with no drug placed for approximately 3 months."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate how OTX-TP, a sustained release travoprost drug\n      product, when placed in the canaliculus of the eyelid compares to timolol drops for the\n      lowering of intraocular pressure (IOP) in patients with open angle glaucoma or ocular\n      hypertension."
        }, 
        "brief_title": "Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma", 
        "condition": "Glaucoma", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must be greater than or equal to 18 years of age at Screening.\n\n          -  Subject must have a documented diagnosis of ocular hypertension, open angle glaucoma.\n\n          -  Subject has a mean baseline (Day -7 and Day 0) Hour 0 (T0) untreated IOP of \u2265 24 mm\n             Hg and \u2264 34 mm Hg in each eye, and (T0 + 4h) and (T0 + 8h) IOP of \u2265 22 mm Hg at\n             Baseline Visit 2. Untreated IOP must be \u2264 34 mm Hg in each eye at all time points at\n             both baseline visits.\n\n          -  Subject has a BCVA of 0.6 logMAR (20/80 Snellen) or better in each eye as measured\n             using an ETDRS chart.\n\n        Exclusion Criteria:\n\n          -  Presence of any uncontrolled systemic or debilitating disease (e.g. cardiovascular\n             disease, hypertension, diabetes, or cystic fibrosis).\n\n          -  Punctum size is smaller than 0.4mm or greater than or equal to 1.0mm.\n\n          -  Any single IOP in either eye at any time point during the Screening or either\n             Baseline (Day -7/Day 0) Visits of >34 mm Hg."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845038", 
            "org_study_id": "OTX-12-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "OTX-TPa", 
                "description": "OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of ~4\u00b5g/day over 2 months. Subjects in this arm will also receive natural tears drops.", 
                "intervention_name": "OTX-TPa ~4\u00b5g/day over 2 mos. with natural tears drops", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "OTX-TPb", 
                "description": "OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of ~3\u00b5g/day over 3 months. Subjects in this arm will also receive natural tears drops.", 
                "intervention_name": "OTX-TPb ~3\u00b5g/day over 3 months with natural tears drops", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Timolol", 
                "description": "Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.", 
                "intervention_name": "Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Timolol", 
                "Maleic acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 19, 2013", 
        "location": {
            "contact": {
                "email": "wassermann@mweb.co.za", 
                "last_name": "Pierre Wassermann, MD", 
                "phone": "+27 (0)31 582 5251/2"
            }, 
            "facility": {
                "address": {
                    "city": "Durban", 
                    "country": "South Africa"
                }, 
                "name": "Umhlanga Hospital Medical Centre"
            }, 
            "investigator": {
                "last_name": "Pierre Wassermann, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Prospective, Multicenter, Randomized, Double-Masked, Multi-Arm Feasibility Study Evaluating the Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension", 
        "other_outcome": {
            "measure": "Best corrected visual acuity", 
            "safety_issue": "Yes", 
            "time_frame": "90 days"
        }, 
        "overall_contact": {
            "email": "dmulani@ocutx.com", 
            "last_name": "Deepa Mulani", 
            "phone": "781-357-4023"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Africa: Medicines Control Council", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean IOP change from baseline", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845038"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "OTX-TP punctum plug contains conjugated fluorescein to serve as a visualization aid through use of a blue light source and yellow filter to confirm product presence daily by subject for 90 days.", 
            "measure": "Visualization of OTX-TP punctum plug by subject", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "source": "Ocular Therapeutix, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ocular Therapeutix, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}